Your browser version may not work well with NCBI's Web applications. More information here...
1: FEBS Lett. 2006 Aug 21;580(19):4751-6. Epub 2006 Aug 4.Click here to read Links

New insights on the use of desipramine as an inhibitor for acid ceramidase.

Department of Microbiology and Immunology, Medical University of South Carolina, P.O. Box 250504, 173 Ashley Avenue, Charleston, SC 29425, USA.

Treatment of different cancer cell lines with desipramine induced a time- and dose-dependent downregulation of acid ceramidase. Desipramine's effect on acid ceramidase appeared specific for amphiphilic agents (desipramine, chlorpromazine, and chloroquine) but not other lysomotropic agents such as ammonium chloride and bafilomycin A1, and was not transcriptionally regulated. The cathepsin B/L inhibitor, CA074ME, but not the cathepsin D inhibitor, pepstatin A, blocked desipramine's effect on acid ceramidase. Desipramine led to a more pronounced downregulation of sphingosine compared to ceramide suggesting acid ceramidase inhibition is important to desipramine's mechanism of action. This study reveals a new mechanism of action for desipramine.

PMID: 16901483 [PubMed - indexed for MEDLINE]